Recent regulatory shifts have critical implications for how biosimilar developers generate and prioritise information. Read ICON’s latest article in PharmTech Magazine, to learn what these changes mean for data collect...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery
This podcast discusses ICON’s selection of Microsoft as a preferred technology partner to scale its agentic AI platform across the clinical trial lifecycle.
-
ICON (ICLR) Partners with Microsoft to Enhance AI Capabilities
This article reports on ICON’s partnership with Microsoft to enhance AI capabilities using Copilot, Azure, and advanced data infrastructure, scaling its Orbis platform to support AI-enabled clinical development.
-
ICON selects Microsoft to power AI-enabled clinical development
This article reports on ICON’s selection of Microsoft as a preferred technology Partner, bringing Microsoft 365 Copilot, Azure, and AI infrastructure to scale its Orbis Platform and enable AI-driven clinical development.
-
ICON selects Microsoft as preferred technology partner to scale agentic AI platform across clinical trial lifecycle
This article reports on an enterprise-wide partnership that brings Microsoft 365 Copilot, Azure, and Fabric infrastructure to ICON's Orbis platform, supporting AI deployment across study design, site operations, and regulatory workflows.
-
From automation to autonomy: How agentic AI is redefining biopharma's digital workforce
This article will explore the emerging architecture of agentic AI in biopharma: what distinguishes agents from traditional rules-based automation, how multi-agent systems orchestrate work across fragmented environments, and why strong governance and upskilled teams are essential to preventing “black-box” operational drift.
-
Liquid biopsy and the future of tumour-agnostic treatments
Explore how liquid biopsy is reshaping oncology and paving the way for truly tumour‑agnostic therapies. Read the latest insights on what this shift could mean for drug development and patient care.
-
Integrated by Design. Strategic pathways for drug-led combination products
Combination products, which integrate a drug and/or biologic component with a medical device component, are increasing globally. Because they do not fit neatly into a single category, regulation of these products can be difficult to navigate.
-
Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape
Regulatory authorities have made it clear that streamlining biosimilar development is a priority, following the example of the EMA and FDA in reducing the requirements for comparative efficacy studies. Read this article to understand the recent changes and their impact.
-
Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance
This article explores practical actions for manufacturing and chemistry, manufacturing, and controls (CMC) teams to align with Q5A(R2)’s updated guidance and stay ahead of the rapidly changing viral safety environment. Implemented well, these actions can shorten testing timelines and strengthen assurance of participant safety.
-
Reimagining vaccine development with AI
Explore how AI is accelerating vaccine development, improving speed, precision, and global readiness.
